|
||||||
|
lncRNA: ENSG00000260219 |
Summary for CD2BP2-DT |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000260219 | Gene symbol | CD2BP2-DT |
| Gene name | CD2BP2 divergent transcript | |
| HGNC | 53029 | |
| Entrez ID | 101928707 | |
| Gene type | lincRNA | |
| Synonyms | 16p11.2|CD2BP2-DT|RP11-347C12.10 | |
| UniProtAcc |
Top |
Structure and expression level for CD2BP2-DT |
| Differentially expressed gene analysis between cancer and normal samples. |
 |
| Ensembl ID | Base mean | log2FC(AD/control) | lfcSE | Stat | P-value | Adjc.p-value | DEG direction | Cancer type |
| ENSG00000260219 | 2.545987e+02 | 1.013703e+00 | 1.336704e-01 | 7.583604e+00 | 3.360000e-14 | 4.210000e-13 | UP | KIRP |
| ENSG00000260219 | 1.119415e+02 | 1.003436e+00 | 1.579389e-01 | 6.353318e+00 | 2.110000e-10 | 1.390000e-09 | UP | UCEC |
| ENSG00000260219 | 2.931680e+02 | 1.690487e+00 | 1.057240e-01 | 1.598963e+01 | 1.510000e-57 | 4.070000e-56 | UP | BRCA |
| Correlation between lncRNAs and cancer stages. |
| LncRNA Ensembl ID | Correlation | P-value | Cancer Type | Adjc.p-value |
| ENSG00000260219 | 4.650869e-01 | 1.286368e-03 | CHOL | 2.092525e-03 |
| ENSG00000260219 | -3.297171e-01 | 1.603319e-03 | KICH | 2.121962e-03 |
Top |
lncRNA-Protein interaction for CD2BP2-DT |
 |
| lncRNA-epigenetic factor interaction (#cancer types with positive correlation >= 5). |
| LncRNA Ensembl ID | LncRNA ENST ID | LncRNA Name | Protein Ensembl ID | Protein Name | CatRAPID Score | Lncpro Score | UniPortID | Gene Subtype | Public source |
| lncRNA-transcript factor interaction (#cancer types with positive correlation >= 5). |
| LncRNA Ensembl ID | LncRNA ENST ID | LncRNA Name | Protein Ensembl ID | Protein Name | CatRAPID Score | Lncpro Score | UniPortID | Gene Subtype | Public source |
| lncRNA-RNA binding protein interaction (#cancer types with positive correlation >= 5). |
| LncRNA Ensembl ID | LncRNA ENST ID | LncRNA Name | Protein Ensembl ID | Protein Name | CatRAPID Score | Lncpro Score | UniPortID | Gene Subtype | Public source |
Top |
|
